2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Immunology, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

1319 Triple-positive antiphospholipid syndrome with catastrophic thrombosis: A systematic review of clinical features, therapeutic strategies, and outcomes

Anas Al-sadi, Elrazi A Ali, MD2, Vasu Bansal3, Sawsan El Sweilmein4, Ayesha Laraib, MBBS5, Aakriti Adhikari, MD6, Goetz Kloecker, MD, MBA, MSPH, FACP7
1 University of Missouri, Kansas City, United States
2 University of Louisville, Brown Cancer Center, Louisville, Kentucky, United States
3 University of Missouri, Kansas City, United States
4 University of Missouri, Kansas City, United States
5 University of Missouri, Kansas City, United States
6 University of Missouri, Kansas City, United States
7 University of Louisville, Brown Cancer Center, Louisville, Kentucky, United States

Background

Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening manifestation of antiphospholipid syndrome characterized by rapid multiorgan thrombosis. Patients with triple-positive antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein I) represent a high-risk subgroup with severe clinical presentations. Available treatment options after anticoagulation include corticosteroids, plasma exchange, intravenous immunoglobulin, and recently anticomplement inhibitors. Data regarding clinical characteristics, treatment patterns, and outcomes in this population remain very limited.

Methods

We conducted a systematic review in accordance with PRISMA guidelines. PubMed, Scopus, and Embase were searched up to April 2026 for studies evaluating patients with triple-positive antiphospholipid syndrome with catastrophic thrombosis. Patients who were not triple-positive for antiphospholipid antibodies and those aged under 18 years were excluded.

Results

A total of 32 articles met the inclusion criteria, comprising 39 patients. The mean age was 39 ± 14.6 years, with 28% male patients. Multiorgan involvement was common, predominantly affecting the kidneys (84.6%), followed by the heart (51.3%), brain (38.5%), and lungs (35.9%). Hematologic abnormalities included thrombocytopenia (71.8%) and microangiopathic hemolytic anemia (38.5%). Triggering factors were identified in 79% of cases, most commonly infection (17.9%), puerperium (10.3%), and surgery (7.7%). All patients received multimodal therapy. Standard treatments included anticoagulation (76.9%), steroids (84.6%), and plasma exchange (74.4%), while rituximab was used in 38.5%, IVIG in 28.2%, and eculizumab in 24 patients (61.5%). Eculizumab was administered in selected patients, primarily in refractory or severe cases. Clinical outcomes showed full recovery in 83.4% of patients, while mortality occurred in 16.7%. Disease relapse was observed in a minority around 10% of patients over a mean follow-up period of 10.7 months. Hematologic parameters and complement levels improved in most treated patients, although renal recovery was variable.

Conclusions

Triple-positive antiphospholipid antibody patients with catastrophic antiphospholipid syndrome (CAPS) present with severe, multisystem disease associated with high morbidity and persistent mortality of approximately 15–20% despite advances in care. Early recognition and prompt initiation of aggressive multimodal therapy, including anticoagulation, corticosteroids, and plasma exchange, remain the cornerstone of management and are associated with favorable outcomes in most patients. Escalation therapies such as rituximab and cyclophosphamide are used selectively but have not demonstrated a clear survival benefit. Eculizumab, a complement inhibitor, is primarily reserved for refractory cases and may provide clinical improvement, supporting a role for complement-mediated mechanisms in disease pathogenesis; however, current data do not show a definitive reduction in mortality with its use. Given the rarity of CAPS, limited sample sizes, and likely underreporting, the evidence base remains insufficient to draw firm conclusions, and treatment decisions should therefore be individualized.

Elrazi A Ali, MD: No relevant conflicts of interest to declare.